CRIT Project

Collaboration on Research Integrity and Transparency

CRIT-Supported Publications

Pending

Click here for the CRIT blog

Other CRIT-Relevant Publications

Dal-Ré R, Ross JS, Marušić A. Compliance with prospective trial registration guidance remained low in high-impact journals and has implications for primary end point reporting. J Clin Epidemiol. 2016;75:100-107.

Phillips AT, Rathi VK, Ross JS. Publication of Clinical Studies Supporting FDA Premarket Approval for High-Risk Cardiovascular Devices between 2011 and 2013: A Cross-sectional Study. JAMA Intern Med. 2016;176:551-552.

Chen R, Desai NR, Ross JS, Zhang W, Chau KH, Wayda B, Murugiah K, Lu DY, Mittal A, Krumholz HM. Publication and Reporting of Clinical Trial Results: Cross Sectional Analysis Across Academic Medical Centers. BMJ. 2016;352:i637.

Downing NS, Shah ND, Krumholz HM, Ross JS. Regulatory Watch: Characterizing the US FDA's approach to promoting transformative innovation. Nat Rev Drug Discov. 2015;14:740-741.

Rathi VK, Krumholz HM, Masoudi FA, Ross JS. Characteristics of clinical studies conducted over the total product life cycle of high-risk therapeutic medical devices receiving FDA premarket approval in 2010 and 2011. JAMA. 2015;314:604-612.

Zarin D, Tse T, Ross JS. Research Letter: Trial results reporting and academic medical centers. NEJM. 2015;372:2371-2372.

Gopal AD, Desai NR, Tse T, Ross JS. Reporting of Noninferiority Trials in ClinicalTrials.gov and Corresponding Publications. JAMA. 2015;313:1163-1165.

Ross JS, Dzara K, Downing NS. Efficacy and safety concerns are important reason why the FDA requires multiple reviews before approval. Health Affairs. 2015;34:681-688.

Smithy JW, Downing NS, Ross JS. Publication of Pivotal Efficacy Trials for Novel Therapeutic Agents Approved Between 2005 and 2011: A Cross-sectional Study. JAMA Intern Med. 2014;174:1518-1520.

Downing NS, Cheng T, Krumholz HM, Shah ND, Ross JS. Descriptions and Interpretations of the ACCORD-Lipid Trial in the News and Biomedical Literature: A Cross-Sectional Analysis. JAMA Intern Med. 2014;174:1176-1182.

Becker JE, Krumholz HM, Ben-Josef G, Ross JS. Reporting of Results in ClinicalTrials.gov and High-Impact Journals. JAMA. 2014;311:1063-1065.

Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS. Clinical trial evidence supporting FDA approval of novel therapeutics, 2005-2012. JAMA. 2014;311:368-377.

Ross JS, Mocanu M, Lampropulos JF, Tse T, Krumholz HM. Time to Publication Among Completed Clinical Trials. JAMA Intern Med. 2013;173:825-828.

Downing NS, Aminawung JA, Shah ND, Braunstein JB, Krumholz HM, Ross JS. Regulatory review of novel therapeutics: comparison of three regulatory agencies. NEJM. 2012;366:2284-2293.

Ross JS, Gross CP, Krumholz HM. Promoting Transparency in Pharmaceutical Industry-Sponsored Research. Am J Public Health. 2012;102:72-80.

Ross JS, Tse T, Zarin DA, Xu H, Zhou L, Krumholz HM. Publication of NIH Funded Trials Registered in ClinicalTrials.gov: Cross Sectional Analysis. BMJ. 2011;344:d7292.

Ross JS, Mulvey GK, Hines EM, Nissen SE, Krumholz HM. Trial Publication After Registration in ClinicalTrials.Gov: A Cross-Sectional Analysis. PLoS Med. 2009;6:e1000144.